Dynavax Technologies Corp... (DVAX)
Bid | 10.24 |
Market Cap | 1.28B |
Revenue (ttm) | 277.25M |
Net Income (ttm) | 27.31M |
EPS (ttm) | 0.2 |
PE Ratio (ttm) | 51.53 |
Forward PE | 20.36 |
Analyst | Buy |
Ask | 12.16 |
Volume | 2,434,334 |
Avg. Volume (20D) | 2,431,178 |
Open | 10.75 |
Previous Close | 10.65 |
Day's Range | 10.26 - 10.76 |
52-Week Range | 9.74 - 14.63 |
Beta | 1.26 |
About DVAX
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a coll...
Analyst Forecast
According to 3 analyst ratings, the average rating for DVAX stock is "Buy." The 12-month stock price forecast is $31, which is an increase of 200.82% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription

1 month ago · seekingalpha.com
Dynavax Technologies: A Post-Earnings Assessment With Growing Market ShareDynavax Technologies posted solid Q4 results and FY 2025 guidance late in February, with Heplisav-B driving revenue growth and profitability. Heplisav-B's market share continues to grow due to its sup...

1 month ago · seekingalpha.com
Dynavax Technologies Corporation (DVAX) Q4 2024 Earnings Call TranscriptDynavax Technologies Corporation (NASDAQ:DVAX ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Paul Cox - Vice President, Investor Relations & Corporate Communicati...